questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Chimiokines
Chimiokines CXC
Chimiokines CXC : Questions médicales fréquentes
Termes MeSH sélectionnés :
Sleep Initiation and Maintenance Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimiokines CXC : Questions médicales les plus fréquentes",
"headline": "Chimiokines CXC : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimiokines CXC : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-09",
"dateModified": "2025-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimiokines CXC"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Chimiokines",
"url": "https://questionsmedicales.fr/mesh/D018925",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokines",
"code": {
"@type": "MedicalCode",
"code": "D018925",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL1",
"alternateName": "Chemokine CXCL1",
"url": "https://questionsmedicales.fr/mesh/D054360",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL1",
"code": {
"@type": "MedicalCode",
"code": "D054360",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.050"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL16",
"alternateName": "Chemokine CXCL16",
"url": "https://questionsmedicales.fr/mesh/D000075743",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL16",
"code": {
"@type": "MedicalCode",
"code": "D000075743",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL5",
"alternateName": "Chemokine CXCL5",
"url": "https://questionsmedicales.fr/mesh/D054365",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL5",
"code": {
"@type": "MedicalCode",
"code": "D054365",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL6",
"alternateName": "Chemokine CXCL6",
"url": "https://questionsmedicales.fr/mesh/D054427",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL6",
"code": {
"@type": "MedicalCode",
"code": "D054427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL9",
"alternateName": "Chemokine CXCL9",
"url": "https://questionsmedicales.fr/mesh/D054370",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL9",
"code": {
"@type": "MedicalCode",
"code": "D054370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL10",
"alternateName": "Chemokine CXCL10",
"url": "https://questionsmedicales.fr/mesh/D054357",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL10",
"code": {
"@type": "MedicalCode",
"code": "D054357",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL11",
"alternateName": "Chemokine CXCL11",
"url": "https://questionsmedicales.fr/mesh/D054371",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL11",
"code": {
"@type": "MedicalCode",
"code": "D054371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL12",
"alternateName": "Chemokine CXCL12",
"url": "https://questionsmedicales.fr/mesh/D054377",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL12",
"code": {
"@type": "MedicalCode",
"code": "D054377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimiokine CXCL13",
"alternateName": "Chemokine CXCL13",
"url": "https://questionsmedicales.fr/mesh/D054382",
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CXCL13",
"code": {
"@type": "MedicalCode",
"code": "D054382",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-4 plaquettaire",
"alternateName": "Platelet Factor 4",
"url": "https://questionsmedicales.fr/mesh/D010978",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-4 plaquettaire",
"code": {
"@type": "MedicalCode",
"code": "D010978",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.120.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Chimiokines CXC",
"alternateName": "Chemokines, CXC",
"code": {
"@type": "MedicalCode",
"code": "D019743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Amin Ullah",
"url": "https://questionsmedicales.fr/author/Amin%20Ullah",
"affiliation": {
"@type": "Organization",
"name": "Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Bairong Shen",
"url": "https://questionsmedicales.fr/author/Bairong%20Shen",
"affiliation": {
"@type": "Organization",
"name": "Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Gholamhossein Hassanshahi",
"url": "https://questionsmedicales.fr/author/Gholamhossein%20Hassanshahi",
"affiliation": {
"@type": "Organization",
"name": "Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Dept. of Hematology, Faculty of Biomed, Biomedical Sciences, Kerman University of Medical Sciences, Kerman, Iran."
}
},
{
"@type": "Person",
"name": "Mojgan Noroozi Karimabad",
"url": "https://questionsmedicales.fr/author/Mojgan%20Noroozi%20Karimabad",
"affiliation": {
"@type": "Organization",
"name": "Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Electronic address: mojgan.noroozi@yahoo.com."
}
},
{
"@type": "Person",
"name": "Tracy M Handel",
"url": "https://questionsmedicales.fr/author/Tracy%20M%20Handel",
"affiliation": {
"@type": "Organization",
"name": "Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer.",
"datePublished": "2023-12-04",
"url": "https://questionsmedicales.fr/article/38000795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/ijgc-2023-004484"
}
},
{
"@type": "ScholarlyArticle",
"name": "Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.",
"datePublished": "2023-12-02",
"url": "https://questionsmedicales.fr/article/38041532",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cncr.35137"
}
},
{
"@type": "ScholarlyArticle",
"name": "Outcome of COVID-19 in Egyptian living-donor kidney transplant recipients and relation to maintenance immunosuppressive drugs: a pilot study.",
"datePublished": "2023-11-03",
"url": "https://questionsmedicales.fr/article/37923735",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-45750-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Factors associated with the maintenance in food texture for dependent older people with dysphagia living in nursing home - A retrospective cohort study.",
"datePublished": "2023-11-02",
"url": "https://questionsmedicales.fr/article/37919247",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/scd.12937"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fulminant ruptured septic aneurysm complicating the catheter related blood stream infection in a patient on maintenance hemodialysis: A case report.",
"datePublished": "2023-10-29",
"url": "https://questionsmedicales.fr/article/37899533",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/11297298231192239"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Chimiokines",
"item": "https://questionsmedicales.fr/mesh/D018925"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimiokines CXC",
"item": "https://questionsmedicales.fr/mesh/D019743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimiokines CXC - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimiokines CXC",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimiokines CXC",
"description": "Comment diagnostiquer une dysrégulation des chimiokines CXC ?\nQuels tests sont utilisés pour mesurer les chimiokines CXC ?\nLes chimiokines CXC sont-elles liées à des maladies spécifiques ?\nPeut-on détecter les chimiokines CXC dans les biopsies ?\nLes niveaux de chimiokines CXC varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimiokines CXC",
"description": "Quels symptômes sont associés à une surproduction de chimiokines CXC ?\nLes chimiokines CXC peuvent-elles causer des symptômes respiratoires ?\nComment les chimiokines CXC affectent-elles le système nerveux ?\nLes chimiokines CXC sont-elles liées à des symptômes cutanés ?\nPeut-on observer des symptômes digestifs liés aux chimiokines CXC ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimiokines CXC",
"description": "Peut-on prévenir les maladies liées aux chimiokines CXC ?\nL'alimentation influence-t-elle les chimiokines CXC ?\nL'exercice physique affecte-t-il les niveaux de chimiokines CXC ?\nLe tabagisme influence-t-il les chimiokines CXC ?\nLe stress chronique affecte-t-il les chimiokines CXC ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimiokines CXC",
"description": "Quels traitements ciblent les chimiokines CXC ?\nLes corticostéroïdes affectent-ils les chimiokines CXC ?\nComment les inhibiteurs de chimiokines CXC fonctionnent-ils ?\nLes traitements anti-inflammatoires influencent-ils les chimiokines CXC ?\nY a-t-il des essais cliniques sur les chimiokines CXC ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimiokines CXC",
"description": "Quelles complications peuvent survenir avec des niveaux élevés de chimiokines CXC ?\nLes chimiokines CXC sont-elles impliquées dans le cancer ?\nComment les chimiokines CXC affectent-elles la cicatrisation des plaies ?\nLes maladies cardiovasculaires sont-elles liées aux chimiokines CXC ?\nLes chimiokines CXC peuvent-elles causer des troubles neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimiokines CXC",
"description": "Quels facteurs de risque augmentent les niveaux de chimiokines CXC ?\nLes infections peuvent-elles influencer les chimiokines CXC ?\nL'exposition à des polluants affecte-t-elle les chimiokines CXC ?\nLe vieillissement influence-t-il les chimiokines CXC ?\nLes maladies métaboliques sont-elles liées aux chimiokines CXC ?",
"url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Sleep+Initiation+and+Maintenance+Disorders&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des chimiokines CXC ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de cytokines peuvent aider à évaluer les niveaux de chimiokines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer les chimiokines CXC ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les dosages ELISA et les tests multiplex sont couramment utilisés pour mesurer les chimiokines."
}
},
{
"@type": "Question",
"name": "Les chimiokines CXC sont-elles liées à des maladies spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent associées à des maladies inflammatoires et auto-immunes."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les chimiokines CXC dans les biopsies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les chimiokines peuvent être détectées dans les tissus par immunohistochimie."
}
},
{
"@type": "Question",
"name": "Les niveaux de chimiokines CXC varient-ils selon l'âge ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de chimiokines peuvent varier avec l'âge et l'état de santé général."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une surproduction de chimiokines CXC ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent inflammation, douleur, fatigue et troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Les chimiokines CXC peuvent-elles causer des symptômes respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont impliquées dans des maladies respiratoires comme l'asthme et la BPCO."
}
},
{
"@type": "Question",
"name": "Comment les chimiokines CXC affectent-elles le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent contribuer à des troubles neurologiques en modulant l'inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Les chimiokines CXC sont-elles liées à des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être impliquées dans des maladies cutanées inflammatoires comme le psoriasis."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes digestifs liés aux chimiokines CXC ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent jouer un rôle dans des maladies inflammatoires de l'intestin."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux chimiokines CXC ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hygiène de vie et la gestion du stress peuvent aider à prévenir certaines maladies."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les chimiokines CXC ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire l'inflammation et les chimiokines."
}
},
{
"@type": "Question",
"name": "L'exercice physique affecte-t-il les niveaux de chimiokines CXC ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut moduler les niveaux de chimiokines et améliorer la santé immunitaire."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les chimiokines CXC ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente les niveaux de chimiokines et contribue à l'inflammation."
}
},
{
"@type": "Question",
"name": "Le stress chronique affecte-t-il les chimiokines CXC ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter l'expression des chimiokines et aggraver l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les chimiokines CXC ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies biologiques et des inhibiteurs de chimiokines sont en développement."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes affectent-ils les chimiokines CXC ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'expression des chimiokines CXC dans l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs de chimiokines CXC fonctionnent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent les récepteurs des chimiokines, réduisant ainsi l'inflammation et la migration cellulaire."
}
},
{
"@type": "Question",
"name": "Les traitements anti-inflammatoires influencent-ils les chimiokines CXC ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent moduler les niveaux de chimiokines et améliorer les symptômes inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur les chimiokines CXC ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques évaluent des traitements ciblant les chimiokines CXC."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des niveaux élevés de chimiokines CXC ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des maladies auto-immunes, des infections chroniques et des cancers."
}
},
{
"@type": "Question",
"name": "Les chimiokines CXC sont-elles impliquées dans le cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent favoriser la progression tumorale et la métastase dans certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les chimiokines CXC affectent-elles la cicatrisation des plaies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut retarder la cicatrisation en exacerbant l'inflammation."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées aux chimiokines CXC ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de chimiokines sont associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les chimiokines CXC peuvent-elles causer des troubles neurologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont impliquées dans des troubles comme la sclérose en plaques et l'Alzheimer."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque augmentent les niveaux de chimiokines CXC ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme et le stress chronique sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles influencer les chimiokines CXC ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections aiguës et chroniques peuvent augmenter l'expression des chimiokines."
}
},
{
"@type": "Question",
"name": "L'exposition à des polluants affecte-t-elle les chimiokines CXC ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des polluants environnementaux peut augmenter les niveaux de chimiokines."
}
},
{
"@type": "Question",
"name": "Le vieillissement influence-t-il les chimiokines CXC ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut entraîner une augmentation des niveaux de chimiokines et de l'inflammation."
}
},
{
"@type": "Question",
"name": "Les maladies métaboliques sont-elles liées aux chimiokines CXC ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète peuvent augmenter les niveaux de chimiokines et l'inflammation."
}
}
]
}
]
}
The aim of this study was to provide real-world efficacy and safety data on niraparib maintenance treatment in patients with non-germline (gBRCA)1/2 mutated platinum-sensitive recurrent ovarian cancer...
This retrospective multi-center cohort study included 94 platinum-sensitive recurrent ovarian cancer patients without known gBRCA1/2 mutation treated in an individual patient access program in Norway....
After median follow-up of 13.4 months (95% confidence interval (CI) 10.0 to 16.8), 68.1% had progressed and 22.3% had died. Of the entire cohort, 61.7% had commenced a new line of treatment, and 24.5%...
In a real-world setting, niraparib maintenance treatment in patients with non-gBRCA1/2 mutated recurrent platinum-sensitive ovarian cancer showed effectiveness comparable with published phase III stud...
The emergence of novel and efficient antibody maintenance approaches has provided more options for post-induction treatment of advanced follicular lymphoma (FL), and further comparisons are required t...
The authors performed two independent searches in PubMed, Web of Science, the Cochrane library databases, Scopus, and Embase for randomized controlled trials (RCTs) evaluating maintenance or consolida...
The authors screened 1515 records and identified 13 eligible RCTs that assessed nine different regimens in 5681 advanced FL patients. Reconstructed individual survival data presented that obinutuzumab...
Although obinutuzumab and rituximab maintenance treatment improved PFS significantly, its clinical benefit requires further validation in larger populations. Furthermore, because few trials informed e...
Coronavirus disease 2019 (COVID-19) in kidney transplant recipients is a subject of much debate and became of interest to nephrologists amidst the pandemic. The main concerns are the influence of the ...
Maintaining the texture of the food that nursing home residents eat is critical for maintaining quality of life and preventing malnutrition. The aim of the present study was to identify the conditions...
The study included 143 people for whom reevaluation 1-year post-baseline was possible from among 256 dependent older people who consumed solid food on admission to a nursing home (baseline). The age, ...
A total of 21 participants (14.7%) changed to a pureed or jelly diet after 1 year. Multivariate analysis showed good activities of daily living (p < .05), good swallowing ability (p < .05), and mainta...
Maintaining activities of daily living, feeding and swallowing ability, and nutritional status appear to be important factors for the maintenance of a solid diet....
Metastatic infections can complicate catheter-related blood stream infections (CRBSI) in dialysis dependent patients. However, an infected/septic aneurysm involving the aorta or its branches as a dire...
Heroin use disorder (HUD) is commonly accompanied by gut dysbiosis, but the roles of gut microbiota in HUD treatment, such as compulsory detoxification and methadone maintenance treatment (MMT), remai...
In this study, we performed 16 s rDNA and whole metagenome sequencing to analyze the gut microbial profiles of HUD patients undergoing heroin addiction, heroin withdrawal (compulsory detoxification), ...
Our findings revealed that, compared to healthy controls, microbial diversity was significantly decreased in HUD patients who were in a state of heroin addiction and withdrawal, but not in those recei...
This study provides evidence from the gut microbiota perspective that MMT is a more effective approach than compulsory detoxification for HUD treatment....
This study aimed to identify the clinical content of patients registered with the Lifetime Health Maintenance Program (LHMP) under the care of a single family physician who introduced and operated the...
We analyzed the electronic medical records of 745 patients who had registered for more than 3 times with the LHMP under the care of a single family physician between January 1, 2010 and December 31, 2...
Patients visited the LHMP for various reasons, including acute symptom management, chronic disease management, psychiatric consultation, counseling on health behaviors, health checkups, and vaccinatio...
The LHMP emphasized the need to systematize regular primary care physicians in Korea. Policy changes are necessary to strengthen primary care, and the LHMP serves as an intermediate step in organizing...
The association between sarcopenic obesity (SO) and cognitive impairment (CI) risk in patients requiring maintenance hemodialysis (MHD) is not known. In this study, we investigated the prevalence of S...
A multicenter, cross-sectional study was conducted. Data from 2743 adult MHD patients were recorded. SO was defined as the co-occurrence of sarcopenia and obesity. Cognitive function was assessed with...
21.58% of the participants met the criteria for SO. The overall prevalence of CI was 23.3% in our study. Participants in the SO group had the highest CI prevalence (34.6%). The association between SO ...
SO and CI are highly prevalent in MHD patients. Participants with SO are at significantly higher risk of CI than those with sarcopenia or obesity alone. Furthermore, this association is consistent acr...
PURPOSE OF REVIEW: The purpose of this study is to evaluate the effectiveness of eHealth interventions for weight loss and weight loss maintenance among adults with overweight or obesity through a sys...
Human hookworm has been proposed as a treatment for ulcerative colitis (UC). This pilot study assessed the feasibility of a full-scale randomized control trial examining hookworm to maintain clinical ...
Twenty patients with UC in disease remission (Simple Clinical Colitis Activity Index [SCCAI] ≤4 and fecal calprotectin (fCal) <100 ug/g) and only on 5-aminosalicylate received 30 hookworm larvae or pl...
At 52 weeks, 4 of 10 (40%) participants in the hookworm group and 5 of 10 (50%) participants in the placebo group had maintained clinical remission (odds ratio, 0.67; 95% CI, 0.11-3.92). Median time t...
A full-scale randomized control trial examining hookworm therapy as a maintenance treatment in patients with UC appears feasible....